APUS

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Today, 7:31 AMQ2 $20.2M net loss and going-concern doubt in 10-Q trigger APUS -24% premarket plunge

Peers: AYTU TXMD CPHI RMTI BGM CTOR SCYX CPIX DERM SCLX

| Held by: VXF

Scroll to Statements

Index	-
Market Cap	4.76M
Enterprise Value	11.05M
Income	-58.17M
Sales	0.00M
Book/sh	70.54
Cash/sh	5.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	May 09, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.04
P/C	0.57
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.51
Current Ratio	0.51
Debt/Eq	0.14
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-36.71
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-108.46% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1844.06%
Sales Y/Y TTM	-
EPS Q/Q	-456.18%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	62.68%
Insider Trans	0.00%
Inst Own	2.82%
Inst Trans	-
ROA	-84.20%
ROE	-100.13%
ROIC	-54.59%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-39.81%
SMA50	-59.70%
SMA200	-79.84%
Trades

Shs Outstand	1.51M
Shs Float	0.56M
Short Float	4.79%
Short Ratio	1.04
Short Interest	0.03M
52W High	59.70 -94.72%
52W Low	4.15 -24.10%
Volatility	9.61% 20.02%
ATR (14)	1.36
RSI (14)	28.39
Beta	0.06
Rel Volume	1032.13
Avg Volume	25.88K
Volume	1,335,399

Perf Week	-25.71%
Perf Month	-52.27%
Perf Quarter	-79.14%
Perf Half Y	-74.39%
Perf YTD	-80.79%
Perf Year	-80.31%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.55
Price	3.15
Change %	-30.77%

Aug-03-26 09:00AM	NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange (GlobeNewswire) -5.83%
Jul-28-26 08:30AM	MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October (GlobeNewswire) +27.19%
Jul-07-26 09:30PM	Inside the ICE House x Las Vegas: MindWave Innovations CEO Dr. Vin Menon (NYSE) -13.66%

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS). The company was founded on May 11, 2020 and is headquartered in Matawan, NJ.

PresidentMr. Erik C. Emerson

Chief Financial OfficerMr. Erick J. Frim

Founder & Co-CEODr. Vinod Menon

Co-Chief Executive OfficerMr. Sungjoon Chae

Chief Operating OfficerCaptain Sandeep Singh Yadav

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Apimeds Pharmaceuticals US Inc

Upgrade your Finviz experience